To determine if NSC109268 sensitizes these ovarian carcinoma cells to cisplatin via p53-dependent mechanisms, we treated 2008 and 2008/C13* cells with the combination of NSC and cisplatin, and monitored p53 level and PARP cleavage. Here, TP53 is linked to ovarian carcinoma.